SNO Bio

SNO Bio is a biotechnology company pioneering the development of a new class of medicines targeting S-nitrosylation (SNO) signaling, a fundamental mechanism for regulating protein function across various physiological systems. Founded by Dr. Jonathan Stamler, a leader in the field of nitric oxide biology, the company leverages a proprietary platform to discover and develop small molecules that modulate SNO levels to treat a wide range of diseases. Their pipeline focuses on areas where SNO signaling is dysregulated, including cardiovascular, respiratory, and metabolic disorders. SNO Bio aims to restore physiological SNO balance to address unmet medical needs in chronic and acute conditions. The company is backed by prominent investors like ARCH Venture Partners and is headquartered in Cleveland, Ohio.